Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
A phase 3 trial of Daraxonrasib, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by Revolution Medicines, Inc., now recruiting.
Overview
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) is a phase 3 interventional study registered as NCT06881784 by Revolution Medicines, Inc., with 590 participants planned, started 2025-05-06 and due to reach its primary completion in 2027-12-01. Interventions recorded: daraxonrasib, docetaxel. Conditions listed: NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Shares Revolution Medicines, Daraxonrasib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Shares Revolution Medicines, Daraxonrasib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Shares Revolution Medicines, Daraxonrasib.
- TrialStudy of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Shares Revolution Medicines, Daraxonrasib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Shares Revolution Medicines, Daraxonrasib.
- TrialStudy of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Shares Revolution Medicines, Daraxonrasib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Acti
Shares Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU
Shares Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.